General information, not insurance advice. bioaccess® is a CRO. We don’t sell or underwrite insurance.
A common stall in early study planning goes like this. A sponsor wants the insurance sorted before it commits to a CRO, a country or a final protocol. It calls a broker, the broker asks for the protocol, and everything stops.
That isn’t the broker being difficult. Clinical trial liability insurance is written for one specific study. The insurer is pricing the chance that a defined product, used in a defined way, on a defined number of people, in defined countries, for a defined time, injures someone. Until those things are written down, there’s nothing to price.
Key takeaways
- No protocol, no policy. Insurers underwrite the study described in the protocol. Some brokers will quote from a near-final draft. A pitch deck or a one-line study description isn’t enough.
- The certificate names the study. In several Latin American countries the policy or certificate must identify the protocol (title and number) and, in Mexico, the number of participants.
- There’s a circular dependency. In Peru, Costa Rica and Argentina the consent form must contain the policy or insurer details. So you need the protocol to get the policy, and the policy to finish the consent form.
- Start early, but in the right order. Countries, then protocol, then quote, then consent form, then certificate, then ethics submission.
Why the protocol comes first
The protocol defines every variable an underwriter prices:
- What’s being tested. Drug, biologic or device; implantable or not; first-in-human or not; prior human data.
- How it’s used. Dose or procedure, invasiveness, exposure duration, comparator or placebo.
- On whom. Patients or healthy volunteers, age range, vulnerable groups, pregnancy exclusions.
- How many and where. Enrollment overall and by country, number of sites, named institutions.
- For how long. Start date, treatment period, follow-up, and expected final report. These drive the policy period and any required tail.
Regulators then tie the policy to that study. Mexican guidance, as summarized by NIH ClinRegs, says the policy and certificate must state the number of participants, the study title and the protocol number. COFEPRIS’s single sponsor form, introduced in April 2025, asks for:
– the Mexican sample size and the global number of participants
– the number of Mexican sites
– study start and end dates
– the risk level
These are the same facts an insurer needs.
The document checklist
Brokers and insurers vary, but this is what you should expect to provide. The Willis clinical trial submission platform, for example, asks for a completed quote request plus the protocol and the informed consent forms, and recommends submitting a complete request at least two weeks before you need the certificate. Marsh notes that a draft protocol is acceptable for a quote, because later changes are usually minor.
About the study
1. Protocol, or near-final draft: title, number, version, phase or stage, design, endpoints, procedures, risk level
2. Investigator’s Brochure, or the device equivalent: preclinical, bench and biocompatibility data and prior human experience
3. Informed consent form, or at least the injury, compensation and insurance section
4. Synopsis showing enrollment by country and overall, participant population and inclusion/exclusion criteria
About where and when
- Country list and number of sites. Include named sites and PIs if known, because these are needed for additional-insured endorsements.
- Timeline: first participant in, last participant out, follow-up duration, and final report date
About the sponsor
- Legal entity, address and ownership. Some markets have know-your-customer checks.
- Existing master, product liability or clinical trial program, and its territory clause
- Contract requirements from sites and CROs, such as additional insureds and limits
About each country
- The local requirement, such as an in-country insurer, a policy term, or consent form wording. See our pillar guide, Clinical trial liability insurance in Latin America: requirements by country.
The consent-form loop
In several countries the consent form can’t be finished until the policy exists:
- Peru: the policy’s in-country coverage, and the local representative if the insurer is foreign, must be stated in the consent form (DS 021-2017-SA, art. 28).
- Costa Rica: each participant receives proof or a copy of the policy showing its number, issuer, term, conditions and claim procedure (Ley 9234, art. 32).
- Argentina: the consent form names the insurance company and its address (ANMAT Disp. 7516/2025, Appendix D).
The practical answer is to request quotes on the near-final protocol. Draft the consent form with placeholders for the policy number and insurer, and fill them in once the policy is bound, before the ethics submission.
A workable sequence
- Choose countries based on the product’s regulatory pathway and enrollment, not on insurance.
- Freeze the protocol design. Enrollment, sites and duration should be stable.
- Brief the broker with the checklist above, and ask which countries need locally admitted paper.
- Get quotes for a master policy plus local policies where needed.
- Bind and get certificates and endorsements naming the protocol, sites and PIs.
- Finish the consent forms with the policy details.
- Submit to ethics and regulators. In Mexico, file the policy or fund within 15 business days after COFEPRIS authorization.
Common mistakes
- Asking for a quote on a “platform” or a pipeline. Underwriters price a study, not a company.
- Relying on a US product liability policy whose territory clause excludes research outside the US, or which a Latin American committee won’t accept as local cover.
- Choosing a site because “it has insurance”. A hospital’s own malpractice cover isn’t the sponsor’s trial policy.
- Letting the policy expire at last-patient-last-visit. Costa Rica and Peru require cover beyond that.
Related guides
- Clinical trial liability insurance in Latin America: requirements by country (our hub guide)
- Mexico: the COFEPRIS 15-business-day insurance rule
- Costa Rica: Ley 9234 insurance requirements
How bioaccess® helps
We assemble the protocol package, country plan and consent form drafts that insurers ask for. We coordinate with your broker so certificates match each ethics committee’s checklist, and we keep the timeline realistic. We don’t sell insurance.
FAQ
Can I get clinical trial insurance before choosing a CRO?
Yes. The CRO doesn’t drive the quote, the protocol does. But you need the protocol, the countries and a realistic enrollment and timeline.
Will an insurer accept a synopsis instead of a full protocol?
Some brokers will give an indication from a detailed synopsis. Binding and certificate issuance generally need the protocol, and some platforms also ask for the consent form.
Do I need a separate policy for each country?
Often, for countries that require locally admitted or in-country cover. Examples are Argentina (“seguro constituido en el país”), Peru (coverage in Peru) and Costa Rica (enforceable locally). A master policy can sit above the local policies.
How far in advance should I start?
Begin broker conversations once the protocol design is stable. Willis recommends submitting a complete request at least two weeks before the certificate is needed. Allow more time for multi-country programs and local policies.
What if the protocol changes after binding?
Tell the broker. Changes to enrollment, countries, sites or duration usually require an endorsement, and some regulators require the policy again for certain amendments. Mexico, for example, requires it for a change of sponsor.
Last verified: 28 October 2026. Written by Julio G. Martinez-Clark, CEO of bioaccess®.